CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADENOCARCINOMA

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

PDF
Published 2016-09-07
Anny Setijo Rahaju Aniek Meidi Gondo Mastutik Sjahjenny Mustokoweni Arifa Mustika

Abstract

Objective: This study aims to prove the correlation between Prostate Specific Antigen (PSA) blood level and Matrix Metalloproteinase-2 (MMP-2) expression in patients with prostate adenocarcinoma. Material & method: Prostate cancer patients’ data from January 2009 to May 2012 were collected at the Department of Pathology, Soetomo General Hospital Surabaya. Data collected included patient medical documents, PSA blood examination, and histopathological examination. Histopathology slides and paraffin blocks of needle biopsies, Transurethral Resection of Prostate (TURP) and radical prostatectomy of prostate cancer patients werere-read, then the samples that met the inclusion criteria were stained by immunohistochemistry using antibodies MMP-2. Results: Data collection was done to obtain data samples of prostate cancer patients in 2009 to 2012 comprising as many as 22 patients between the ages of 52-91 years. Prostate adenocarcinoma in age of 70-79 was found in 8 patients, with a mean age of 68 years. PSA values obtained from medical documents were between 8.6-594.41 ng/ml. Spearman's test performed in this study showed a positive correlation (one-tailed) (correlation coefficient (r) 0431, p < 0.05) between blood PSA level and MMP-2 expression in patients with prostate adenocarcinoma. Conclusion: Blood PSA level correlates positively with MMP-2 expression in prostate adenocarcinoma.


##plugins.themes.bootstrap3.article.details##

Keywords

Prostate specific antigen, matrix metalloproteinase-2, prostate adenocarcinoma

References

Epstein, JI, Algaba, F, Allbrook, WC, Bastacky, S. Acinar adenocarcinoma, in WHO classification of tumours, pathology and genetics tumours of the urinary system and male genital organs, Ed. Ebk JN, IARC Press, Lyon; 2004. p. 161-92.

Rosai, J. Male reproductive system. In Rosai and Ackerman’s surgical pathology. 9th Ed. Elsevier, China. 2011; 1: 1361-87.

Epstein, JI. The lower urinary tract and male genital system, in Robbins pathologic basic of disease, 8th Ed. Saunders: Philadelphia; 2010. p. 993-1003.

Young, RH. Atlas of tumors pathology, tumors of the prostate gland, seminal vesicles, male uretra, and penis, 3rd Series. Armed Forces Institute of Pathology: Washington DC; 2000. p. 111-200.

Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue, Prostate Cancer and Prostatic Diseases 6; 2003. p. 217–22. doi:10.1038/sj.pcan.4500657.

http://emedicine.medscape.com/article/457394-overview

Nelson RA, Fingleton B, Rothenberg ML, Matrisian LM, Matrix metalloproteinases: Biologic activity and clinical implications, Journal of Clinical Oncology. 2000; 218(5): 1135-49.

Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000; 2(4): 252-7.

Verma RP, Hansch C. Matrix metalloproteinase (MMPs): chemical-biological function and (Q) SARs. Bioorg Med Chem. 2007; 15(6): 2223-68.

Tero Leinonen, Risto Pirinen, Jan Bohm. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. In Histol Histopathol. 2008; 23: 693-700.

http://atlasgeneticsoncology.org/Genes/MMP2ID41396ch16q13.html

Daniel Kaemmerer, Luisa Peter, Emelie Lupp. Original Article: Comparing of IRS as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012; 5(3): 187-94

Stadiana Zivkovic. Original article: Correlation between proatate-specific antigen and histopathological difference of prostate carcinoma. In Arch Oncol. 2004; 12(3): 148-51.

Nigel P. Murray, Gloria M. Calaf, Leonardo Badinez. P504S expressing circulating prostate cells as a marker for prostate cancer. In Oncology Reports. 2010; 24; 687-92.

Dominique trudel, Yves fradet, Franc. Significance of MMP-2 expression in prostate cancer. An immunohistochemical study. In Cancer research. 2003; 63; 8511-15.

Yixuan Gong, Uma D. Chippada-Venkata, William K. Oh. Reviews: Roles of matrix metalloproteinase and their natural inhibitors in prostate cancer progression. Cancers. 2014; 6: 1298-327.

B Brehmer, S Biesterfeld, G Jakse. Prostate cancer and prostatic disease: Expression of matrix metalloproteinase (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. 2003; 6; 217-22.

Romano Oguic, Vladimir Mozetic, Eleonora Cini Tesar. Research article: Matrix metalloproteinase 2 and 9 immunoexpression in prostate carcinoma at the positive margin of radical prostatectomy specimen. In Hindawi Publishing Corporation Pathology Research International; 2014. Article ID 262195; 8.

http://www.ncbi.nlm.nih.gov/gene/4313

Amalinei C, Caruntu ID, Balan RA. Biology of metalloproteinases. Romanian Journal of Morphology and Embryology. 2007; 48(4): 323-34.

Section
Articles
Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University